x

Posted 12 March, 2024

Cencora, Inc. appointed new CEO

CEO Change detected for ticker NYSE:COR in a 8-K filed on 12 March, 2024.


  On March 11, 2024, the Board of Directors (the "Board") of Cencora, Inc. (the "Company") unanimously selected Robert P. Mauch to succeed Steven H. Collis as the Company's President and Chief Executive Officer ("CEO"), effective October 1, 2024 (the "Effective Date"), at which time he will also join the Board.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Cencora, Inc.
Retail/Wholesale • Drug Retail
AmerisourceBergen Corp. engages in the provision of pharmaceutical products and business solutions that improve access to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical Distribution Services segment distributes an offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, and long-term care and alternate site pharmacies. The Other segment focuses on global commercialization services and animal health, and includes AmerisourceBergen Consulting Services ABCS, World Courier, and MWI. The company was founded by in Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.
Market Cap
$47.4B
View Company Details
Cencora, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.


On March 11, 2024, the Board of Directors (the "Board") of Cencora, Inc. (the "Company") unanimously selected Robert P. Mauch to succeed Steven H. Collis as the Company's President and Chief Executive Officer ("CEO"), effective October 1, 2024 (the "Effective Date"), at which time he will also join the Board. Mr. Collis, who has served as CEO since July 2011, will retire from the role of CEO and become Executive Chairman of the Board as of the Effective Date, to serve for a period of one year.


Mr. Mauch, age 57, currently serves as the Company's Executive Vice President and Chief Operating Officer. He previously served as the Company's Group President from February 2019 to September 2022 and as Group President, Pharmaceutical Distribution & Strategic Global Sourcing from June 2017 to February 2019. Mr. Mauch joined the Company in 2007 when it acquired Xcenda and has since held various leadership roles.


Mr. Mauch will not receive any additional compensation for his service on the Board. The Company will file an amendment to this Current Report on Form 8-K to disclose compensation arrangements relating to the foregoing events within four business days after such information becomes available.